Xenetic Biosciences in-licenses DNase oncology platform from CLS Therapeutics for $500K cash + 875K shares + milestones

Xenetic Biosciences, Inc.

Upfront payment: $500K cash + 875,000 common shares (250,000 issued to OPKO per third-party obligation).
Milestone payments up to $13M per program in cash plus up to 950,000 additional shares for regulatory milestones.
Licensed platform includes systemic DNase (co-admin with chemo/IO) and DNase-armored CAR T therapies.
Xenetic plans Phase 1 study of lead asset in locally advanced or metastatic solid tumors.
Tiered royalties on net sales (mid-single to low-double digits); sublicense revenue share in mid-teens to low-double digits.

item 1.01 item 2.01 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.